Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRx-102 in rheumatoid arthritis
NCT00747214Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2004
- Primary completion
- Sep 2006
- Sponsor
- CombinatoRx
- Modality
- Orthosteric Ligands
- Conditions
- rheumatoid arthritis (RA)
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing CRx-102 + DMARD with Placebo + DMARD (2 arms). Primary endpoint: Change in Serum C Reactive Protein From Baseline at Day 42. Started Nov 2004; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
CRx-102 + DMARD
CRx-102 plus stable DMARD therapy
Placebo + DMARD
Placebo plus stable DMARD therapy
03
Endpoints
Primary
Change in Serum C Reactive Protein From Baseline
Secondary
Improvement of ACR 20 Scores
Change in DAS28 Score
Change in Fatigue (MAF Scale) Score
Beyond the preview
Go deeper on NCT00747214.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00747214.